CCL21 and melanoma: In a follow-up study, Shields et al. showed that melanoma tumors in mice produced CCL21 and initiated an immunotolerant milieu; in contrast, CCL21-deficient tumors induced antigen-specific immunity, suggesting that CCL21-related immune responses were facilitating cancer progression [227].